Global Recombinant Erythropoietin Drugs Sales Market Report 2024

Report ID: 857569 | Published Date: Jan 2025 | No. of Page: 146 | Base Year: 2024 | Rating: 4.3 | Webstory: Check our Web story

Erythropoietin (EPO), also known as haematopoietin or haemopoietin, is a glycoprotein cytokine secreted by the kidney in response to cellular hypoxia; it stimulates red blood cell production (erythropoiesis) in the bone marrow. Low levels of EPO (around 10 mU/mL) are constantly secreted sufficient to compensate for normal red blood cell turnover. Common causes of cellular hypoxia resulting in elevated levels of EPO (up to 10 000 mU/mL) include any anemia, and hypoxemia due to chronic lung disease.

Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with the peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. Liver production predominates in the fetal and perinatal period; renal production predominates in adulthood. It is homologous with thrombopoietin.

Market Analysis and Insights: Global Recombinant Erythropoietin Drugs Market
The global Recombinant Erythropoietin Drugs market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global Recombinant Erythropoietin Drugs Scope and Market Size
The global Recombinant Erythropoietin Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Recombinant Erythropoietin Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
rhEPO
Erythropoiesis-Stimulating Agents (ESA)

Segment by Application
Chronic Kidney Disease
Cancer Related Anemia
Others

The Recombinant Erythropoietin Drugs market is analysed and market size information is provided by regions (countries). Segment by Application, the Recombinant Erythropoietin Drugs market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Amgen
Johnson & Johnson
Kyowa Hakko Kirin
Roche
3SBio Group
Celltrion, Inc
Teva Pharmaceutical Industries Ltd
F. Hoffmann-La Roche Ltd
LG Life Sciences Ltd
Biocon Limited
Intas Pharmaceuticals Ltd
Sun Pharmaceutical Industries Ltd
Dr. Reddy's Laboratories Ltd

Frequently Asked Questions
Recombinant Erythropoietin Drugs report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Recombinant Erythropoietin Drugs report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Recombinant Erythropoietin Drugs report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports